We appreciate you taking the time to help America’s Health Rankings better understand our audiences. Your feedback will allow us to optimize our website and provide you with additional resources in the future. Thank you.
Explore national- and state-level data for hundreds of health, environmental and socioeconomic measures, including background information about each measure. Use features on this page to find measures; view subpopulations, trends and rankings; and download and share content.
New Jersey Value:
Percentage of adults age 60 and older who reported ever receiving a respiratory syncytial virus (RSV) vaccine
New Jersey Rank:
Percentage of adults age 60 and older who reported ever receiving a respiratory syncytial virus (RSV) vaccine
63.4% - 39.2%
39.1% - 35.4%
35.3% - 33.0%
32.9% - 29.5%
29.4% - 22.6%
No Data
US Value: 33.0%
Top State(s): New Mexico: 63.4%
Bottom State(s): Mississippi: 22.6%
Definition: Percentage of adults age 60 and older who reported ever receiving a respiratory syncytial virus (RSV) vaccine
Data Source and Years(s): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, National Immunization Survey–Adult COVID Module, 8/18/2024-1/4/2025
Suggested Citation: America's Health Rankings analysis of U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, National Immunization Survey–Adult COVID Module, United Health Foundation, AmericasHealthRankings.org, accessed 2026.
Respiratory syncytial virus (RSV) is a common respiratory virus that causes cold-like symptoms. RSV can lead to pneumonia and worsen underlying conditions such as asthma, chronic obstructive pulmonary disease (COPD) and heart failure.
While RSV tends to be mild for healthy adults and children older than 6 months, older adults who contract RSV are more likely to develop severe illness and require hospitalization. Approximately 110,000-180,000 adults age 50 and older are hospitalized for RSV every year in the United States.
The economic burden of RSV among adults age 60 and older in the U.S. is estimated at $6.6 billion annually in 2022 dollars.
The Centers for Disease Control and Prevention recommends the RSV vaccine for all adults age 75 and older, as well as for adults ages 50-74 with elevated risk factors for severe RSV. Factors that increase the risk of severe RSV include:
In addition to the vaccine, the National Council on Aging recommends taking precautions such as frequent handwashing, avoiding contact with those who are sick, staying home when ill and wearing a mask in crowded indoor spaces during RSV season to avoid contracting or spreading the illness.
Carrico, Justin, Katherine A. Hicks, Eleanor Wilson, Catherine A. Panozzo, and Parinaz Ghaswalla. “The Annual Economic Burden of Respiratory Syncytial Virus in Adults in the United States.” The Journal of Infectious Diseases 230, no. 2 (August 16, 2024): e342–52. https://doi.org/10.1093/infdis/jiad559.
America’s Health Rankings builds on the work of the United Health Foundation to draw attention to public health and better understand the health of various populations. Our platform provides relevant information that policymakers, public health officials, advocates and leaders can use to effect change in their communities.
We have developed detailed analyses on the health of key populations in the country, including women and children, seniors and those who have served in the U.S. Armed Forces, in addition to a deep dive into health disparities across the country.
